An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 685-694

  Finley, Michael F A ^a,b   Lubin, Mary Lou ^a,c   Neeper, Michael P ^a,d   Beck, Edward ^a,c   Liu, Yi ^a   Flores, Christopher M ^a   Qin, Ning ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Centocor Research and Development Inc ^*

^d CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; OMEGA CONOTOXIN MVIIA; ROSCOVITINE; TETRANDRINE;

ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CALCIUM TRANSPORT; CELL STRAIN HEK293; ELECTROPHYSIOLOGY; EX VIVO STUDY; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PROTEIN EXPRESSION; RAT; SPINAL CORD; SPINAL GANGLION; WESTERN BLOTTING;

EID: 78650492823     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0311     Document Type: Article

References (27)

1. Snutch, TP: Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005;2:662-670.
2. Woodcock J, Witter J, Dionne R: Stimulating the development of mechanism based individualized pain therapies. Nat Rev Drug Discov 2007;6:703-710.
3. Jarvis MF: Emerging drug discovery strategies for alleviating neuropathic pain. Drug Dev Res 2006;68:287-288.
4. Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D: Cell specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 2004;41:127-138.
5. Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK: Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur J Pharmacol 1988;146:181-183.
6. Smith MT, Cabot PJ, Ross FB, Robertson, AD, Lewis, RJ: The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002;96:119-127.
7. Womack, MD, McCleskey, EW: Interaction of opioids and membrane potential to modulate Ca2+ channels in rat dorsal root ganglion neurons. J Neurophysiology 1995;73:1793-1798.
8. Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, Han W, Toriyama H, Tanabe T: Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J 2001;20:2349-2356.
9. Williams JA, Day M, Heavner JE: Ziconotide: an update and review. Expert Opin Pharmacother 2008;9:1575-1583.
10. Winquist RJ, Pan JQ, Gribkoff VK: Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol 2005;70:489-499.
11. Zhang S-P, Kaufman J, Yagel SK, Codd EE: High-throughput screening for N-type calcium channel blockers using scintillation proximity assay. J Biomol Screen 2006;1 1:672-677.
12. Lubin ML, Reitz TL, Todd MJ, Flores CF, Qin N, Xin H: A nonadherent cell based HTS assay for N-type calcium channel using calcium 3 dye. Assay Drug Dev Technol 2006;4:689-694.
13. Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, Cerne R, Lavery D, Valenzano KJ, Woodward RM, Ilyin VI: Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol 2006;72:770-782.
14. Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, Williams ME, Herrington J, Smith MM, McManus OB, Swenson AM: A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol 2008;6:195-212.
15. Lansman JB, Hess P, Tsien RW: Blockade of current through single calcium channels by Cd2 +, Mg2 + and Ca2 +. J Gen Physiol 1986;88: 321-347.
16. Feng ZP, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW: Determinants of inhibition of transiently expressed voltage-gated calcium channels by o-conotoxins GVIA and MVIIA. J Biol Chem 2003;278:20171-20178.
17. Buraei Z, Elmslie KS: The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels. J Neurochem 2008;105: 1450-1461.
18. Weinsberg F, Bickmeyer U, Wiegand H: Effects of Tetrandrine on calcium channel currents of bovine chromafin cells. Neuropharmacology 1994;33: 885-890.
19. Mathes C: QPatch: the past, present and future of automated patch clamp. Exp Opin Ther Targets 2006;10:319-327.
20. Mathes C, Friis S, Finley M, Liu Y: QPatch: the missing link between HTS and Ion Channel Drug Discovery. Comb Chem High Throughput Screen 2009;12: 78-95.
21. Mogg AJ, Mill C, Beattie RE, Wiernicki TR, Blanco M, Beck JP, Broad LM: Pharmacological profiling of native TRPV1 from adult rat spinal cord [abstract]. Presented at the annual meeting of the Society for Neuroscience, 2007. Washington D.C.
22. Bleakman D, Bowman D, Bath CP, Brust PF, Johnson EC, Deal CR, Miller RJ, Ellis SB, Harpold MM, Hans M, Grantham CJ: Characteristics of a human N-type calcium channel expressed in HEK293 cells. Neuropharmacology 1995;34:753-765.
23. Stocker JW, Nadasdi L, Aldrich RW, Tsien RW: Preferential interaction of o-conotoxins with inactivated N-type Ca2 + channels. J Neurosci 1997;17:3002-3013.
24. McCleskey EW, Fox AP, Feldman DH, Cruz LJ, Olivera BM, Tsien RW, Yoshikami D: co Conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc Natl Acad Sci USA 1987;84:4327-4331.
25. Buraei Z, Schofield G, Elmslie KS: Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. Neuropharmacology 2007; 52:883-894.
26. Zhou W, Jones SW: Surface charge and calcium channel saturation in bullfrog sympathetic neurons. J Gen Physiol 1995;105:441-462.
27. Thomas P, Smart TG: HEK293 cell line: a vehicle for the expression of recombinant proteins. J Pharmacol Toxicol Methods 2005;51:187-200.